Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, August 4, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ed Arce Reiterated (ABUS) at Strong Buy and Held Target at $6 on, Aug 4th, 2023
Ed Arce of HC Wainwright & Co., Reiterated "Arbutus Biopharma Corporation" (ABUS) at Strong Buy and Held Target at $6 on, Aug 4th, 2023.
Ed has made no other calls on ABUS in the last 4 months.
There is 1 other peer that has a rating on ABUS. Out of the 1 peers that are also analyzing ABUS, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Roy Buchanan of "JMP Securities" Reiterated at Buy and Held Target at $6 on, Thursday, July 6th, 2023
